The light-hearted debate, “Primary Cardiovascular Prevention with SGLT2 Inhibitors or GLP-1 Receptor Agonists: Are We Ready for Prime Time?” took place Monday during the 80th American Diabetes ...
Please provide your email address to receive an email when new articles are posted on . Most of the studies compared TNF inhibitors with non-TNF-inhibitor DMARDs. The results may indicate that ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results